Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BraimTOR-ONKO: Rapamycin for paediatric high-grade glioma
2024-515951-39-00Phase 2Completed
- Sponsor
- Children's Memorial Health Institute
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in high-grade glioma (HGG) and malignant glioma (2 arms), sponsored by Children's Memorial Health Institute. Primary endpoint: Grade 3–4 adverse reactions incidence. Started Jan 2025; status: completed.
02
Drugs
sirolimus
03
Conditions
high-grade glioma (HGG)malignant glioma
Beyond the preview
Go deeper on 2024-515951-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515951-39-00.